Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

DS-1971

Alternative Names: ds-1971, ds1971, ds 1971, ds1971a, ds-1971a
Clinical Status: Inactive
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

A highly potent, selective NaV1.7 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32392056/)

Mechanisms of Action: NaV1.7 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Radiculopathy|Spinal Stenosis|Neuropathic Pain|Neuralgia

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
JapicCTI-163193

P2

Terminated

Radiculopathy|Spinal Stenosis

2017-03-31

DS1971-A-U202

P2

Withdrawn

Neuralgia|Neuropathic Pain

2017-01-01

2024-02-16

DS1971-A-E106

P1

Completed

Healthy Volunteers

2015-12-01

2024-02-16

Primary Endpoints|Treatments
DS1971-A-E105

P1

Completed

Healthy Volunteers

2015-07-01

2024-02-16

Primary Endpoints|Treatments
DS1971-A-E104

P1

Completed

Healthy Volunteers

2015-01-01

2024-02-16

Primary Endpoints|Treatments
DS1971-A-E103

P1

Completed

Healthy Volunteers

2014-11-01

2024-02-16

Primary Endpoints|Treatments
DS1971-A-E102

P1

Completed

Healthy Volunteers

2014-11-01

2024-02-16

Primary Endpoints|Treatments
DS1971-A-E101

P1

Completed

Healthy Volunteers

2014-07-01

2024-02-16

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css-MRTpo method and chimeric mice with humanised livers.

01/01/2023

PubMed

 Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective Na(V)1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver.

03/01/2022

PubMed

 CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective Na(V)1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions